

PT BIO FARMA (PERSERO)

Analysts: Emanuel Paco Tan / Agung Iskandar

Phone/Fax/E-mail: (62-21) 7278 2380 / 7278 2370 / emanuel.tan@pefindo.co.id / agung.iskandar@pefindo.co.id

CREDIT PROFILE

Corporate Rating *idAAA/Stable*

Rated Issues

MTN 2018 *idAAA*
MTN Syariah
Mudharabah 2018 *idAAA(sy)*

Rating Period

July 9, 2019 – July 1, 2020

Rating History

JUL 2018 *idAAA/Stable*

FINANCIAL HIGHLIGHTS

As of/for the year ended

	Mar-2019 (Unaudited)	Dec-2018 (Audited)	Dec-2017 (Audited)	Dec-2016 (Audited)
Total Adjusted Assets [IDR Bn]	7,504.8	7,347.7	6,388.5	5,871.3
Total Adjusted Debt [IDR Bn]	922.0	655.0	0.0	0.0
Total Adjusted Equity [IDR Bn]	5,937.5	5,909.3	5,589.0	5,251.0
Total Sales [IDR Bn]	269.4	3,235.2	3,011.6	2,315.8
EBITDA [IDR Bn]	85.1	890.2	840.4	807.4
Net Income after MI [IDR Bn]	20.7	543.2	525.4	501.0
EBITDA Margin [%]	31.6	27.5	27.9	34.9
Adjusted Debt to EBITDA [X]	*2.7	0.7	0.0	0.0
Adjusted Debt to Adjusted Equity [X]	0.2	0.1	0.0	0.0
FFO to Adjusted Debt [%]	*27.9	105.1	N/A	N/A
EBITDA to IFCCI [X]	5.7	32.6	104.1	86.4
USD Exchange Rate [IDR/USD]	14,244	14,481	13,548	13,436

FFO = EBITDA – IFCCI + Gross Interest Income – Current Tax Expense

EBITDA = Operating Profit + Depreciation Expense + Amortization Expense

IFCCI = Gross Interest Expense + Other Financial Charges + Capitalized Interest; (FX Loss not included)

MI = Minority Interest * Annualized N/A = Not applicable

The above ratios have been computed based on information from the company and published accounts. Where applicable, some items have been reclassified according to PEFINDO's definitions.

PEFINDO affirms "idAAA" rating for PT Bio Farma (Persero)

PEFINDO has affirmed its "idAAA" ratings for PT Bio Farma (Persero) (BIFR) and BIFR's Medium-Term Notes (MTN) Year 2018, and "idAAA(sy)" rating to BIFR's MTN Syariah Mudharabah Year 2018. The outlook for the corporate rating is "stable".

An obligor rated *idAAA* has the highest rating assigned by PEFINDO. The obligors' capacity to meet its long-term financial commitment, relative to that of other Indonesian obligors, is superior.

The suffix (sy) indicates that the rating mandates compliance with Islamic principles.

The corporate rating reflects BIFR's critical role in providing vaccines for the nation, its very strong market position in the vaccine industry, and its strong financial profile. However, the rating is constrained by the exposure to risks in regulatory changes and smaller export market shares.

The rating could be lowered if PEFINDO views a reduction in the government support, such as through a material divestment of the government's ownership and/or lower barrier to entry through the regulations, such as allowing other vaccines companies to supply vaccines for the government projects. The rating could also be under pressure if it incurs a substantially larger debt than projected and/or its capital expenditure (capex) are not well executed, resulting in a weaker financial profile, particularly if its debt to EBITDA ratio exceeds 2.5x on a sustained basis.

As Indonesia's sole state-owned vaccine producer, BIFR is focused on developing vaccine research and technology, conducting new vaccine research in ensuring self-sufficiency of vaccine needs in Indonesia as well as availability of vaccines to meet the world's vaccines needs in terms of quality and affordability. BIFR supplies all the vaccines for Indonesia's National Vaccine Program and it has a long-term contract to supply vaccines to various countries through UNICEF. Currently, 14 types of BIFR's vaccines have received prequalification from World Health Organization (WHO). It was 100% owned by Indonesian Government as of March 31, 2019.

DISCLAIMER

PT Pemeringkat Efek Indonesia (PEFINDO) does not guarantee the accuracy, completeness, timeliness or availability of the contents of this report or publication. PEFINDO cannot be held liable for its use, its partial use, or its lack of use, in combination with other products or used solely, nor can it be held responsible for the result of its use or lack of its use in any investment or other kind of financial decision making on which this report or publication is based. In no event shall PEFINDO be held liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses including but not limited to lost profits and opportunity costs in connection with any use of the contents of this report or publication. Credit analyses, including ratings, and statements in this report or publication are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities or to make any investment decision. The contents cannot be a substitute for the skill, judgment and experience of its users, its management employees and/or clients in making investment or other business decisions. PEFINDO also assumes no obligation to update the content following publication in any form. PEFINDO does not act as fiduciary or an investment advisor. While PEFINDO has obtained information from sources it believes to be reliable, PEFINDO does not perform an audit and does not undertake due diligence or independent verification of any information used as the basis of and presented in this report or publication. PEFINDO keeps the activities of its analytical units separate from its business units to preserve independence and objectivity of its analytical processes and products. As a result, certain units of PEFINDO may have information that is not available to other units. PEFINDO has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. PEFINDO may receive compensation for its ratings and other analytical work, normally from issuers of securities. PEFINDO reserves the right to disseminate its opinions and analyses. PEFINDO's public ratings and analyses are made available on its website, <http://www.pefindo.com> (free of charge) and through other subscription-based services, and may be distributed through other means, including via PEFINDO publications and third party redistributors. Information in PEFINDO's website and its use fall under the restrictions and disclaimer stated above. Reproduction of the content of this report, in full or in part, is subject to written approval from PEFINDO.